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Abstract 
Background: A normal number of T-cell receptor excision circles (TRECs) and K-deleting recombination excision 
circles (KRECs) is considered a biomarker for adequate new T- and B-cell production. In newborns, detection of TRECs 
and KRECs by real time PCR from dried blood spotted on filter paper is used for the screening of severe immunode-
ficiency. In adults, elderly and during diseases, where the number of TRECs is lower than in newborns and children, a 
large amount of DNA and a sensitive method of amplification are necessary to identify newly produced lymphocytes.
Methods: DNA was prepared from blood of 203 healthy adults (range: 18–91 years old) absorbed for 10 s on flocked 
swabs and let to dry, or from peripheral blood mononuclear cells. DNA was subjected to digital PCR and to well estab-
lished conventional real time PCR-based method using TREC- and KREC-specific primers and probes. The number of 
TRECs and KRECs was expressed per mL of blood. Statistical analysis was performed by nested ANOVA, Pearson coef-
ficient of determination, and by linear regression tests.
Results: The novel method for the storage of dried blood on nylon flocked swabs and the use of digital PCR allow 
quantification of TRECs and KRECs with high degree of sensitivity, specificity, accuracy, and precision. TRECs and KRECs 
were amplified by digital PCR in all tested blood samples, including those obtained from elderly individuals (>70 years 
old) and that were negative by real time PCR. Furthermore, values of TRECs and KRECs obtained by digital PCR were in 
the range of those acquired by real time PCR.
Conclusions: Our findings demonstrate that DNA isolation from dried blood on flocked swabs followed by digital 
PCR-based analysis represents a useful tool for studying new lymphocyte production in adults and elderly individuals. 
This suggests the potential use of the methodology when monitoring of clinical variables is limited by the number of 
molecules that can be amplified and detected, such as in patients with immunodeficiency or under immunosuppres-
sive therapies.
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Background
T-cell receptor (TCR) and B-cell receptor gene rear-
rangements involve cutting and splicing of the DNA 
encoding the alternate variable, diversity, and joining seg-
ments. Excised DNA, formed during the programmed 
gene rearrangements in the thymus and in the bone 
marrow, constitutes the TCR excision circles (TRECs) 
and K-deleting recombination excision circles (KRECs), 
respectively [1, 2]. These circles are stably retained within 
peripheral blood lymphocytes, are not replicated during 
mitosis and are diluted as T and B cells proliferate. The 
number of TRECs and KRECs per unit of blood volume 
correlates with the production of new T and B cells; a 
normal TREC and KREC number is considered a bio-
marker for a good thymic and bone marrow output, while 
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production [1, 2]. TRECs have been measured starting 
from different biological materials, such as fresh whole 
blood (WB) [3], peripheral blood mononuclear cells 
(PBMC) [1, 4] or dried blood samples [5]. TRECs and 
KRECs were initially measured in separate quantitative 
real time PCR (qRT-PCR) assays [1, 2]; successively, we 
modified these assays to allow the simultaneous measure 
of TRECs and KRECs in PBMC (“reference” method) [6, 
7], while others used the method to measure the target 
molecules on dried blood spotted on filter paper cards [8, 
9]. TREC/KREC combined assay has been used to estab-
lish appropriate diagnosis and treatments of patients with 
severe primary immune deficiencies [7, 10, 11], to moni-
tor immune-reconstitution in patients receiving chemo-
therapy and post-hematopoietic stem cell transplantation 
[12], or undergoing immunomodulant [13] and anti-HIV 
[14] therapies. The protocol performed using dried blood 
spots is currently used for newborn screening of immu-
nodeficiency [8, 9, 15], considering the high number of 
TRECs in newborns, the low cost of the test, and the easy 
transportation and storage of spotted cards. The use of 
dried blood samples on filter paper prepared from adults, 
elderly people, and patients undergoing immunosuppres-
sive therapies may be challenging due to the low quan-
tity of TRECs and KRECs that can be isolated and the 
low quantity of DNA that can be extracted by punches of 
cards. The recovered DNA quantity represents a critical 
factor for the success of TREC and KREC testing. Gener-
ally, the more DNA is recovered, the better is the chance 
for obtaining a robust and reliable result; on the contrary, 
a small amount of DNA would result either in stochasti-
cally variable amplification or in the loss of signal due to 
insufficient template.
Digital PCR (dPCR) is a novel, alternative method to 
qRT-PCR for precise quantification of nucleic acids, ena-
bling many applications that require high sensitivity and 
have restricted sample availability. In dPCR, the speci-
men is distributed across a large number of partitions, 
each of them containing one (or a few) or no copies of the 
target DNA. By counting the number of partitions con-
taining (positive partitions) or not (negative partitions) 
the amplified target PCR product, the absolute abun-
dance of the target molecule can be measured in a given 
sample without the need of the standard curve required 
in the qRT-PCR assay. There are mainly two types of plat-
forms for dPCR: one incorporating a microfluidic chip 
and one in which the PCR is performed in microdrop-
lets [16]. They have many potential applications, includ-
ing the detection of low-level molecules [17], rare genetic 
sequences [18], circulating miRNAs [19], copy number 
variations [20], as well as gene levels in single cell [21].
In this work, we describe the feasibility of processing 
blood samples absorbed on flocked swabs (FS), dried, and 
stored at room temperature for subsequent DNA isola-
tion, followed by TREC and KREC quantification using 
the  Quantstudio® 3D Digital PCR, a micro-well chip-




Anonymized blood samples were obtained from patients 
with immunodeficiency and from adult controls (CTRL) 
without pathologies referring to the ASST Spedali Civili 
of Brescia hospital for routine diagnostic testing. Blood 
samples were collected using ethylenediaminetetraacetic 
acid (EDTA) tubes. Two types of nylon FS (FLOQSwab™ 
Genetics, Copan, Brescia, Italy) were tested: a single FS 
with an integrated active drying system in the tube stop-
per (4N6FLOQSwab code 4504C) and a dual FS without 
the drying system (4N6FLOQSwab code 4511C). All FS 
were immersed in blood for a time ranging from 10 to 
60  s; the first type of FS was immediately inserted into 
containers, while the other FS, without the integrated 
drying system, were left to dry for at least 2 h and then 
inserted back into containers. FS were stored at room 
temperature until DNA extraction. For sample stability 
evaluation, DNA was extracted after 1 week, and then 
after 1, 3, 6, 9 and 12 months from FS preparation.
Blood aliquots were also used to prepare PBMC by 
Ficoll-Hypaque gradient centrifugation which were kept 
in liquid nitrogen; other aliquots were directly subjected 
to DNA extraction. Simultaneously, fresh blood drops 
were placed on Nucleic-Cards™ (Copan Italia, Brescia, 
Italy), which were stored at room temperature until pro-
cessing. Discs of 2 mm were punched from each card and 
subjected to DNA extraction. DNA extracted from HeLa 
cell line, which does not contain TRECs or KRECs, was 
used to assess dPCR specificity and to establish back-
ground signals.
DNA extraction
DNA from FS was extracted either with QIAamp DNA 
Blood Mini Kit and with Gentra Puregene Blood Kit 
according to manufacturer’s instructions (Qiagen, 
Hilden, Germany). Red blood cell lysis was not per-
formed with the Gentra kit. In addition, we developed 
the homemade protocol for DNA extraction as detailed 
below. FS shafts were snapped at the molded breakpoint, 
inserted in the Nucleic Acid Optimizer (NAO™) bas-
ket (Copan), placed in microtubes and filled with 300 
µL of saline solution, 300 µL of ATL buffer and 7 µL of 
Puregene Proteinase K 20  mg/mL (Qiagen). After an 
overnight incubation at 56  °C on a shaker at 1400  rpm, 
samples were centrifuged at 13,000 rpm for 5 min. Dur-
ing this centrifugation the grid bottom of the basket 
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allows the passage of sample elution buffer from the FS. 
FS and baskets were removed from the microtubes and 
protein precipitation was obtained by incubating sam-
ples on ice for 20 min with 233 µL of ammonium acetate 
7.5  M. After centrifugations at 13,000  rpm for 10  min, 
supernatants were transferred to new microtubes con-
taining 600 µL of isopropanol and 1 µL of 5 mg/mL glyco-
gen (Ambion Inc., Austin, TX), mixed gently until DNA 
was visible as threads or clumps, and then incubated for 
10  min at room temperature. Vortexing was avoided to 
minimize fragmentation of the extracted DNA [22]. After 
centrifugation at 13,000  rpm at 4  °C for 20  min, super-
natants were discarded and pellets washed with 500 µL 
of ethanol 70%, incubated at room temperature for 5 min 
and centrifuged at 13,000 rpm at 4 °C for 10 min. Dried 
pellets were subsequently dissolved using 40 µL of TE 
(10  mM Tris, pH 8.0, 0.1  mM EDTA, pH 8) and incu-
bated at 65 °C for 10 min on a shaker.
DNA from 300  µL of WB and from six 2-mm punch 
discs of dried blood on cards (corresponding to 8.4 µL of 
blood) was extracted using the Gentra Puregene Blood 
Kit following the manufacturer’s instructions. DNA from 
3 × 106 of PBMC and HeLa cell line was extracted using 
the QIAamp DNA Blood Mini Kit.
DNA from FS and cards without absorbed blood were 
used to test eventual cross contaminations during extrac-
tion procedures.
Quantity, purity, and integrity of DNA extracted from FS
DNA extracted from FS, cards, WB, PBMC, and Hela cells 
was analyzed spectrophotometrically (Nanodrop 2000c, 
Thermo Fisher Scientific, Waltham, MA) at 260  nm 
to evaluate DNA concentration and by measuring the 
260/280 nm absorbance ratio to estimate DNA purity.
The level of precision of the homemade method for 
DNA extraction from FS was determined in several repli-
cates by evaluating intra- and inter-assay variation. Yield 
was expressed as percentage of recovery that is the pro-
portion of extracted over expected DNA. The expected 
DNA was calculated based on the white blood cell 
(WBC) count and a mean DNA content of 6.6 pg/cell.
For DNA integrity and size range analysis, 500  ng of 
DNA were subjected to electrophoresis on a 0.8% agarose 
gel in 1× TBE buffer (0.089  M Tris base; 0.089  M boric 
acid; 0.002 M EDTA, disodium salt dihydrate; final pH 8.3) 
containing ethidium bromide. The DNA size marker was 
Lambda DNA HindIII Digest (Sigma-Aldrich, Saint Louis, 
MO). To further evaluate genomic DNA integrity and to 
exclude the presence of any inhibitory material interfering 
with amplification reaction, 50 ng of DNA were amplified 
in a 50 μL mix containing 500 nM of primers specific for 
a fragment of albumin gene (forward: 5′-TGA AAC ATA 
CGT TCC CAA AGA GTT T-3′ and reverse: 5′-CTC 
TCC TTC TCA GAA AGT GTG CAT AT-3′), 0.2  mM 
deoxynucleotide triphosphates, 1.5  mM  MgCl2, and 1.5 
U AmpliTaq Gold DNA polymerase with reaction buffer 
II (Applied Biosystem™, Austin, TX). A no-template con-
trol was used to check for contamination. The amplifi-
cation program consisted of one step at 95  °C for 7 min, 
followed by 30 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C 
for 30 s and a final extension at 72 °C for 10 min. Amplified 
products were separated on 2% agarose gel containing eth-
idium bromide; the DNA size marker was DNA molecular 
weight marker VIII (0.019–1.11 kbp; Roche Diagnostics, 
Basel, Switzerland). Gels were photographed by G:Box™ 
gel documentation system (Syngene, Cambridge, UK).
Quantification of TRECs and KRECs
TRECs and KRECs were measured after amplification 
with both TaqMan qRT-PCR and dPCR assays. The well 
established “reference” qRT-PCR was carried out as pre-
viously reported, using DNA extracted from PBMC, with 
a triple plasmid containing fragments of TRECs, KRECs, 
and TCR constant alpha gene created in our laboratory 
and used to prepare the standard curve [7]. With this 
method, the number of lymphocytes plus monocytes 
(which are the cells obtained in PBMC preparation) con-
tained in 1 mL of blood was used to calculate the number 
of TRECs or KRECs per milliliter of blood (copies/mL), 
that is = (TRECs or KRECs per 1 × 106 PBMC) × (lym-
phocyte plus monocyte count in 1 mL of blood)/106 [7].
dPCR was performed using micro-well- chip-based 
 QuantStudio® 3D Digital PCR (Applied Biosystems™, 
Thermo Fisher Scientific,  Waltham, MA), following 
the manufacturer’s instructions and the same prim-
ers and probes for the TaqMan assay, with the excep-
tion of 5′ reporter dye of KREC probe labelled with VIC 
instead of HEX. Four microliter of DNA (correspond-
ing to about 500  ng depending on sample concentra-
tion) were added to a mixture consisting of 8 µL of 2× 
 QuantStudio® 3D Digital PCR master mix v2, 900 nM of 
both TREC and KREC forward and reverse primers and 
200  nM of both TREC FAM-TAMRA and KREC VIC-
TAMRA probes, and 0.29 μL of BSA (2  mg/mL). Using 
automatic chip loader, 14.5 μL of this mix were added on 
each  QuantStudio® 3D Digital PCR 20K Chip v2. Chips 
were loaded on ProFlex™ 2× flat PCR System and cycled 
according to the following parameters: 95  °C for 8  min, 
followed by 45 cycles of 62  °C for 1  min and 95  °C for 
15 s, and a final extension at 62 °C for 2 min.
Singleplex dPCR was performed amplifying 4 μL 
(500  ng) of DNA in a mixture consisting of 8 µL of 2× 
 QuantStudio® 3D Digital PCR master mix v2, 900 nM of 
forward and reverse primers for TRECs (or KRECs) and 
200  nM of probe for TRECs FAM-TAMRA (or KRECs 
VIC-TAMRA), and 0.29 μL of BSA (2 mg/mL).
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Absolute quantification was determined using 
 Quantstudio® 3D Digital PCR System and analyzed with 
 QuantStudio® 3D AnalysisSuite Cloud Software (Thermo 
Fisher Scientific).
Sensitivity and specificity of dPCR platform were 
evaluated with the plasmid created for qRT-PCR diluted 
in the DNA from HeLa cell line. The copy number was 
estimated according to the molecular weight, amount, 
and length of plasmid. Plasmid dilutions were set up in 
125  ng/µL of DNA from HeLa cells; the plasmid copy 
numbers charged on chip were 0, 5, 10, 25, 50, 100, 500, 
1000, and 2500 and the amount of charged DNA was 
500 ng. The sensitivity of dPCR was compared with that 
of qRT-PCR by testing, with the two methods, progres-
sive dilutions of plasmid DNA copies.
The reproducibility of dPCR assay was determined by 
intra- and inter-assay variation experiments, performed 
starting from the DNA obtained from FS prepared using 
the same blood sample.
Direct quantification of TRECs and KRECs per mL of blood
When amplified DNA is extracted from blood, either in 
liquid form or absorbed and dried onto a FS, TRECs and 
KRECs per mL of blood can be calculated according to 
the following equation, which takes into account the vari-
able recovery of DNA due to an inevitable DNA loss dur-
ing extraction:
where:  QTYtarget  =  copy number of target sequence in 
the loaded DNA, as determined by qRT-PCR or dPCR 
(in the case of dPCR, this is the copy number per chip, 
obtained by multiplying the copy number per parti-
tion by the number of filled partitions),  DNAextracted 
(ng) = total amount of extracted DNA determined after 
measuring the DNA concentration using the spectropho-
tometer,  DNAloaded (ng) = actual amount of DNA loaded 
for the PCR reaction, Vol (μL) = volume of WB used for 
DNA extraction from blood in liquid form or absorbed 
onto a FS, Rec = proportion of DNA recovered after the 
extraction.
Rec can be calculated as:
The  DNAtot (ng) is the theoretical total DNA content in 
the liquid blood volume used for the extraction/blood 
absorbed onto the FS, and can be estimated as follows:





















where:  DNAlcell  =  mean DNA content in human cells 
(6.6 × 10−3 ng).
After substituting these terms in the first equation, we 
obtain the following formula:
Alternatively, because 1  mL  =  103 μL, we can directly 
obtain [Target/(mL)] as:
where the final estimation of the number of targets 
depends neither on the exact volume collected by the 
FS (which varies in distinct FS), nor on the estimation of 
DNA recovery; it only depends on the amount of loaded 
DNA and on the number of WBC/mL of blood, assum-
ing that the absorption process does not alter the concen-
tration of cells present in the sample (i.e. absorbed blood 
WBC concentration being equal to the circulating blood 
WBC concentration).
Statistics
The percentage of DNA recovery was analyzed by nested 
ANOVA, thus accounting for the presence of replicates 
and for the different days in which the experiments were 
performed. The variance components estimated by the 
nested ANOVA were employed to calculate the coef-
ficients of variation, following the Clinical and Labora-
tory Standards Institute EP05-A3 document suggestions 
(http://shop.clsi.org/method-evaluation-documents/
EP05.html). Correlations were analyzed with the Pearson 
coefficient of determination. TREC and KREC changes 
with age were assessed by linear regression. Results were 
considered significant if p < 0.05.
Results
Blood absorption on FS
FS immersed into blood achieved the maximum quan-
tity of absorption, and subsequent plateau, within 10  s. 
At this time point, the mean volume of absorbed blood, 
measured by quantifying the weight of blood contained 
in the tube prior to introduction and after removal of the 
FS, was 143 μL (range: 117–160 μL). No differences were 
found if FS with or without the integrated active drying 
system in the tube stopper were used (data not shown). 
However, for safety reasons, all the following experiments 
were performed on FS with the drying system. Indeed, 
before being inserted into containers, FS without active 
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the desk. Furthermore, the immediate insertion of swabs 
with active drying system into containers prevents poten-
tial microbial growth.
Quantity and quality of recovered DNA
We first examined the extraction method yielding the 
greatest quantity of DNA from dried blood absorbed 
on FS. The mean amount of DNA per μL of elution vol-
ume and total DNA yield, recovered for each extraction 
method performed on dried blood of the same CTRL 
absorbed on FS, is shown in Table 1.
Data indicated that the optimized homemade method, 
as described within the material and method section, 
allowed the maximum yield of DNA recovered from FS, 
and was therefore used for validation experiments of 
dPCR method. No differences were found if DNA was 
extracted from CTRL (126.57  ±  10.49  ng/µL) or from 
patients (123.68 ± 22.24 ng/µL). The mean concentration 
of DNA recovered with this protocol from CTRL-derived 
FS was 26.3  ng/μL of absorbed blood (range: 19.3–
36.9  ng/μL). Of note, the concentration did not change 
if DNA extraction was done 1 week, or 1, 3, 6, 9 and 
12  months after FS preparation (data not shown). The 
mean concentration, obtained from mean of absorbed 
blood of 143 μL, was comparable to that obtained start-
ing from 300 μL of WB (mean: 25.2  ng/μL of blood; 
range: 21.2–29.1 ng/μL) and from six 2-mm punch discs 
obtained from filter paper cards (mean: 26.8  ng/μL of 
blood; range: 23.2–57.1 ng/μL). The mean percentage of 
DNA recovery (i.e. proportion of extracted over expected 
DNA) from the three sources was comparable (p = ns), 
being 69% (95% CI 60–78%) for FS, 60% (49–70%) for 
WB, and 74% (62–85%) for cards.
DNA integrity, size range, and detectability by PCR 
were measured by gel electrophoresis. FS-derived DNA 
showed a smear-like profile, with peak intensity always 
greater than 1000 base pairs (Fig. 1a), which is accepted 
as a minimum size range for several genetic and epige-
netic studies [22]. After PCR amplification, extracted 
DNA exhibited on agarose gel a clearly recognizable 
82 base pair band of the albumin housekeeping gene 
(Fig.  1b). This demonstrated the quality of the isolated 
DNA and the absence of inhibitory substances. Further-
more, the amplification of this short fragment indicated 
that the DNA prepared from FS was suitable for the 
amplification of TRECs and KRECs, leading to ampli-
fied products of 88 and 90 base pairs, respectively. Intra- 
and inter-assay coefficient of variation for DNA recovery 
from FS, were 13.1% (95% CI 9.9–19.4%) and 13.6% (5.7–
36.7%), respectively, as calculated in 26 replicates.
Validation of dPCR for TREC and KREC quantification
DNA was subjected to dPCR as described within the 
Material and Method section. The substitution of the 
Table 1 Extraction efficiency of DNA from the flocked swabs impregnated with whole blood using three different extrac-
tion methods
Experiments were done in triplicate










QIAamp DNA Blood Mini Kit 25 18.00 1.74 450 87.18
Gentra Puregene Blood Kit 30 92.75 6.73 2783 201.80











Fig. 1 DNA integrity and size range assessed by agarose gel electrophoresis. a Lane M DNA high molecular weight marker, lane 1 positive control 
(DNA extracted from whole blood), lanes 2–6 5 DNA prepared from the same blood sample and absorbed on different FS, and lanes 7–11 DNA of 5 
different blood samples absorbed on FS. b Lane M DNA molecular weight marker, lanes 1–10 10 μL of albumin-amplified products of DNA extracted 
from different FS samples, lane NTC “no template control” DNA sample extracted from FS without absorbed blood
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HEX fluorochrome with VIC at 5′ end of KREC probe in 
respect to that used for the TaqMan assay improved both 
the fluorescence intensity and the separation between 
cluster of negative and positive data points. Quality con-
trol of chip-based dPCR was performed with a software 
which assesses whether the data on a chip are reliable 
based upon loading, signal, and noise characteristics. In 
order to obtain a precise quantification, the threshold 
was settled at 15,000 data points.
TREC- and KREC-free DNA extracted from HeLa cells 
was used to assess the specificity of dPCR. HeLa DNA 
resulted positive for 1 TREC/chip and 3 KRECs/chip, 
which can be considered as a background signal (Addi-
tional file 1: Figure S1A). HeLa-generated data were also 
used to establish the threshold values, manually set at 
fluorescence intensity of 5000 for TRECs and 4000 for 
KRECs. These threshold values allow for a precise separa-
tion between positive and negative dot plots (Additional 
file 1: Figure S1B).
Sensitivity of dPCR in detecting TRECs and KRECs 
was evaluated amplifying known quantities of the plas-
mid DNA containing the sequences of TRECs and 
KRECs, diluted in the HeLa cell DNA. When increasing 
plasmid copies were loaded per chip, we found a high 
correlation between plasmid copy numbers determined 
by dPCR and the estimated ones  (r2 = 0.9903 for TRECs 
and 0.9848 for KRECs; Fig. 2).
Experiments performed using several dilutions of 
TRECs- and KRECs-containing plasmid demonstrated 
that the detection limit was one copy of TRECs and one 
of KRECs with dPCR, while 2.5 copies of the target mol-
ecules were detected by qRT-PCR. However, with qRT-
PCR approach, the lowest levels of TRECs and KRECs 
are evidenced at cycle thresholds (Ct) greater than 35, 
which approaches the sensitivity limits of the qRT-PCR 
system. Both digital and qRT-PCR gave rise to undetect-
able results at 0 copies of TREC and KREC plasmid.
The efficiency of multiplex dPCR was assessed by com-
paring the number of TRECs and KRECs obtained with 
duplex (TRECs: 5614/mL  ±  117, and KRECs: 30,468/
mL ± 3230) and singleplex (TRECs: 4509/mL ± 208 and 
KRECs: 26,595/mL ± 2912) reactions.
Intra-assay variation of dPCR was 11% for TRECs 
and 8% for KRECs, while inter-assay variation was 13% 
for TRECs and 15% for KRECs (Additional file  2: Table 
S1). These data are in agreement with published results 
obtained using the established “reference” qRT-PCR 
based assay [7, 12].
dPCR for TREC and KREC quantification
As first step, we quantified TRECs and KRECs using the 
“reference” qRT-PCR method assessed on PBMC-derived 
DNA [7], and subsequently we selected 10 samples with 
increasing number of TRECs (from undetectable to 
30,817/mL) and KRECs (from undetectable to 22,099/
mL). The samples with undetectable/low levels of both 
targets were obtained from children with primary immu-
nodeficiency, while those with higher levels of TRECs 
and KRECs were from CTRL. For these samples, WB- 
and FS-absorbed-DNA samples also were available. Of 
note, dPCR allowed the detection of TRECs and KRECs 
in all analyzed samples, even in those in which they were 
undetectable with qRT-PCR (subject #1, #2, #3 and #4; 
Table 2).
Furthermore, although performed on three differently 
manipulated blood specimens (PBMC, WB and dried 
blood on FS), with DNA prepared with three different 
DNA extraction methods (QIAamp and Gentra Puregene 
Blood Kit, and homemade protocol), using two different 
types of quantitative PCR, and done in several different 
experimental procedures, results obtained from each dif-
ferent subject were similar, in particular in the samples 
in which TRECs and KRECs were lower than 10,000/mL. 
TRECs and KRECs were also evaluated by normalizing 












10 0 10 1 10 2 10 3 10 4
Copies
TRECs KRECs
Fig. 2 Sensitivity of dPCR for TREC and KREC amplification. Zero, 5, 10, 25, 50, 100, 500, 1000, and 2500 copy number of the plasmid containing frag-
ments of TRECs and KRECs were diluted in HeLa cell DNA to obtain 500 ng of DNA and then subjected to dPCR for TREC and KREC quantification
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data of different experimental procedures of dPCR for 
the amount of DNA prepared from FS and directly from 
WB. With few exceptions, the values of TRECs and 
KRECs per μg of DNA obtained with the two techniques 
were comparable (data not shown).
Then, 5 replicate aliquots of samples, chosen from 
those with undetectable number of TRECs or KRECs at 
the qRT-PCR assay and from which sufficient DNA was 
available, were analyzed in different experimental proce-
dures both by dPCR and qRT-PCR. Results demonstrated 
that TRECs and KRECs remained constantly undetect-
able by qRT-PCR, but were always detectable by dPCR 
(Additional file 3: Table S2).
Subsequently, dPCR was used to quantify TRECs and 
KRECs on 203 FS-absorbed blood samples from CTRL of 
different age (from 18 to 91  years old); the results were 
compared with values of TRECs and KRECs obtained 
with the “reference” method in 207 age-matched CTRL 
(from 20 to 83  years old). The age-adjusted mean value 
(±standard error) of TRECs was 7383 ± 553/mL (range: 
82–49,929/mL) when tested with dPCR, and 6535 ± 548/
mL (range: 1–61,171/mL) when tested with qRT-PCR 
(p  =  ns). The age-adjusted mean value of KRECs was 
16,834  ±  1023/mL (range: 341–81,634/mL) with dPCR 
vs 15,117  ±  1015/mL (range: 0–92,180) with qRT-PCR 
(p = ns). Figure 3 shows the perfect overlap of the results 
achieved with the two methods. Furthermore, the data 
obtained by dPCR confirmed that the levels of KRECs 
were stable over time (slope  =  −23 [95% CI −144 to 
99], p = ns), while TRECs progressively decreased with 
increasing age (slope  =  264 [95% CI −319 to −208], 
p  <  0.0001). Although present at very low levels in the 
Table 2 Values of TRECs and KRECs
dPCR digital PCR, FS flocked swabs, PBMC peripheral blood mononuclear cells, qRT-PCR quantitative real time PCR, und undetectable, WB whole blood
a DNA from PBMC was analyzed with the “reference” method
Subject Source of DNA TRECs/mL qRT-PCR TRECs/mL dPCR KRECs/mL qRT-PCR KRECs/mL dPCR
PBMCa und – 8294 –
#1 WB und 261 17,636 16,684
FS und 74 17,183 15,041
PBMC 3674 – und –
#2 WB 7854 6564 und 1312
FS 7892 8488 und 1488
PBMC 18 – 1136 –
#3 WB 252 462 4880 4048
FS und 106 2739 3580
PBMC 149 – 6897 –
#4 WB und 527 10,670 13,244
FS und 405 11,330 14,249
PBMC 5220 – 7279 –
#5 WB 11,999 8231 22,300 17,112
FS 4467 8046 17,494 15,230
PBMC 5322 – 25,159 –
#6 WB 10,221 4824 41,282 32,753
FS 4817 6403 31,934 28,184
PBMC 9544 – 17,189 –
#7 WB 39,062 33,378 66,717 16,582
FS 18,071 15,147 61,276 40,361
#8 PBMC 19,264 – 4357 –
WB 27,926 23,385 7088 3096
FS 27,828 22,671 3619 3959
#9 PBMC 24,809 – 23,333 –
WB 25,778 25,811 20,599 17,346
FS 24,563 20,244 26,541 16,852
#10 PBMC 30,817 – 22,099 –
WB 52,494 38,190 42,171 32,453
FS 41,428 35,845 42,037 35,649
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group of 30 subjects >70 years old (Additional file 4: Fig-
ure S2), TRECs were detected in all samples analyzed 
with dPCR.
Discussion
In this study we demonstrated that quantity and qual-
ity of DNA prepared from dried blood stored on FS are 
adequate to quantify circularized fragments of DNA, 
such as TRECs and KRECs, even if they are contained in 
peripheral blood in number as low as few copies per mL. 
Therefore, the proposed strategy for storing dried blood 
on FS and TREC and KREC quantification by dPCR can 
be successfully applied to adults and elderly subjects 
for a proper evaluation of new T- and B-lymphocyte 
generation.
It is well known that blood samples adsorbed on filter 
paper or nylon FS, and left to dry, represent a conveni-
ent alternative option to fresh blood specimens when col-
lection and shipment of biological materials are difficult, 
when resources are limited, or if used for applications 
in large surveys. Indeed, dried blood carries a reduced 
biohazard risk as compared to liquid samples; it simpli-
fies shipments to reference laboratories for testing, and 
importantly, it requires minimal storage facilities because 
nucleic acids are stable at room temperature. For these 
reasons, dried blood spotted as a drop onto filter paper 
is largely used in newborn screening for genetic diseases 
[23]. The most recent improvement within this specific 
field of research is the newborn screening for severe 
combined immunodeficiency (SCID) through the detec-
tion of TRECs. In fact, the use of TREC test was intro-
duced for early diagnosis of infants with SCID, following 
the evaluation of incidence and costs of early versus late 
treatment [24, 25]. Several protocols for easy detection 
of TRECs in newborn blood spotted on filter paper have 
been developed and validated [24, 26–28]. The absolute 
number of TRECs varies greatly, with several fold-dif-
ferences, ranging from 119 to 1900 TRECs/μL, based on 
different laboratories [25], depending on the parameters 
of the assays, such as DNA isolation method, qRT-PCR 
primers and probes, standard curve used, singleplex or 
multiplex PCR. The volume of total dried blood could 
be an important limiting factor leading to assay failure 
when, for instance, the biological substrates are con-
tained at very low quantity and if a large representation 
of target molecules is mandatory. Indeed, while normal 
newborns have a high rate of new T-cell production, 
resulting in TREC numbers of about 10% of their total 
T-cell numbers, adults have progressively lower ratio 
of TRECs to T cells, reflecting peripheral T-cell expan-
sion [1]. Therefore, due to the lower representation of 
TRECs within their peripheral blood, several punches 
from filter paper would be required in order to obtain a 
sufficient DNA amount for TREC quantification. To our 
knowledge, data regarding the values of TRECs in the 
blood of adults spotted on filter paper are not available. 
In addition, those obtained from liquid and dried blood 
samples or PBMC [1, 3, 4, 29] are of difficult comparison 
due the methods of TREC calculation or because TREC 
measurement has been presented in a number of dif-
ferent ways. Indeed, TRECs are reported as normalized 
amount (calculated as a difference between Ct values of 
reference gene and Ct of TRECs), as absolute number per 
unit number of cells, as TREC molecules per μg of DNA 
within PBMC or T-lymphocyte subsets, or as TRECs 
per mL of blood. The values that we have generated by 
directly quantifying TRECs from FS-derived dried blood 
amplified by dPCR alternative method are given per mL, 
are measured removing any confounding attributable to 
cell proliferation, and using very small quantities of start-
ing whole blood (about 150 μL). The possibility to store 
dried blood on FS and to send it by regular mail (Guid-
ance on Regulations for the Transport of Infectious Sub-
stances 2015–2016—WHO/HSE/GCR/2015.2) lends this 
approach to be easily used in clinical settings where lim-































Fig. 3 Levels of TRECs and KRECs in adults. Black round dots and con-
tinuous lines results obtained by digital PCR (dPCR) starting from DNA 
obtained from dried blood adsorbed on FS; square dots and dotted 
lines results obtained by quantitative real time PCR (qRT-PCR) starting 
from DNA prepared from peripheral blood mononuclear cells
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studies, in immunodeficient patients and/or where lon-
gitudinal information is required, and when the analysis 
cannot be performed locally.
We found that the extent of age-related TREC decrease 
determined by dPCR in DNA obtained from dried blood 
adsorbed on FS was comparable to that reported by Lor-
enzi et  al. [3], stating a 1.5-Log change of TRECs over 
the age range they have measured in liquid WB. Further-
more, newly produced data can be compared with retro-
spective ones because the mean values of dPCR-derived 
TRECs and KRECs perfectly matched those found in age-
matched controls analyzed with the conventional “refer-
ence” method used in our diagnostic laboratory. This was 
quite unexpected, due to the following reasons:—DNA 
was extracted from differentially manipulated blood spec-
imens (WB, PBMC, and dried blood) and using diverse 
methods (different buffers and reagents may potentially 
exert an effect on the end-result);—the amount of tar-
get DNA used for the two amplification protocols was 
different;—the methods of TREC and KREC evaluation 
were different (with qRT-PCR the values are extrapolated 
from a standard curve, while with dPCR the results are 
expressed as absolute values);—the mathematical for-
mula used to calculate the number of TRECs and KRECs/
mL of blood are diverse. In addition, it must be taken 
into account that the data were all obtained in differ-
ent experimental procedures, in order to reproduce the 
“real world” conditions necessary for a test to be used for 
routine analyse. This introduces further variations in the 
results. Therefore, although the experiment performed 
with dilutions of plasmid DNA using dPCR allowed the 
detection of one copy of TRECs and one of KRECs, while 
2.5 copies of the targets were detected by qRT-PCR, due 
to above reported differences, one cannot be confident 
enough to possibly state that dPCR is more sensitive than 
qRT-PCR for the quantification of TRECs and KRECs in 
peripheral blood. However, with qRT-PCR approach, the 
lowest levels of TRECs and KRECs are evidenced at Ct 
greater than 35. At values  >35, the qRT-PCR-generated 
data have poor precision, are not always reproducible, 
and the method cannot be considered quantitative. Fur-
thermore, we previously reported [7] that the detection 
limit for qRT-PCR method for TRECs was approximately 
10 TRECs or KRECs copies and Lorenzi et al. [3] demon-
strated that as the number of TRECs quantified per sam-
ple fell below 10, variations in the final result increased. 
Finally, an advantage of dPCR is that, when working at 
the limit of assay sensitivity, the probability of TREC and 
KREC detection could be easily increased by quantifying 
these targets from replicate aliquots of individual sam-
ples and adjusting the derived values accordingly.
To our knowledge, no data are available on KREC eval-
uation from adult dried blood samples, thus this is the 
first report in which both TRECs and KRECs have been 
simultaneously quantified starting from blood of adults 
adsorbed on FS.
Conclusions
We demonstrated that FS-absorbed dried blood sam-
ples allow the detection of both TRECs and KRECs using 
dPCR in adult samples, including subjects over 70  s, 
notoriously known to present low number of TRECs, 
and also in those in whom these targets were undetect-
able when evaluated by qRT-PCR. The proposed method, 
based on combining DNA isolation from dried blood on 
FS followed by dPCR-based analysis, enables the quanti-
fication of nucleic acid targets without the need of using 
calibration curves and shows a high degree of efficiency, 
sensitivity, accuracy, and precision. Importantly, it rep-
resents a novel and valid option for studying the extent 
of newly produced T and B cells in adults and elderly 
population.
Future studies are needed to evaluate this method-
ology in the context of a larger cohort of adult patients 
with multiple sclerosis, rheumatoid arthritis or patients 
who underwent bone marrow transplantation, in order 
to monitor their immune status and their immune recov-
ery during immunomodulating-immunosuppressive 
therapies.
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